CS-231;[R-(R*,S*)]-5-Chloro-N-[3-(diMethylaMino)-2-hydroxy-3-oxo-
1-(phenylMethyl)propyl]-1H-indole-2-carboxaMide;5-Chloro-N-[(1S,2R)-3-(diMethylaMino)-2-hydroxy-3-oxo-1-(phenylMethyl)propyl]-1H-indole-2-carboxaMide;CP 91149;5-chloro-N-((2S,3R)-4-(dimethylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl)-1H-indole-2-carboxamide;CP 91149 USP/EP/BP;CP-91149 CP91149;CP-91149, 10 mM in DMSO
CP-91149 is a selective inhibitor of glycogen phosphorylase (GP) with an IC50 of 0.13 μM in the presence of glucose, showing 5- to 10-fold reduced potency in the absence of glucose; it exhibits potent inhibitory activity against human liver glycogen phosphorylase a (HLGPa) (200-fold more potent than caffeine, IC50 = 26 μM), human muscle phosphorylase a and b (IC50 = 0.2 μM and ~0.3 μM, respectively), and brain GP in A549 cells (IC50 = 0.5 μM); it dose-dependently inhibits glucagon-stimulated hepatic glycogenolysis in isolated rat and primary human hepatocytes (IC50 ~2.1 μM); induces inactivation of phosphorylase and concurrent activation of glycogen synthase, leading to increased glycogen synthesis (7-fold at 5 mM glucose and 2-fold at 20 mM glucose); partially counteracts the effects of GP overexpression; promotes dephosphorylation and activation of glycogen synthase (GS) in non-engineered or GP-overexpressing human muscle cells, but only in glycogen-depleted cells; causes significant glycogen accumulation in A549 and HSF55 cells at 10–30 μM; increases G1-phase cell population with a concomitant decrease in S-phase cells in HSF55 cells, correlating with upregulated p21 and p27 expression; lowers blood glucose by 100–120 mg/dL in diabetic ob/ob mice following oral administration (25–50 mg/kg) via inhibition of hepatic glycogenolysis without inducing hypoglycemia; does not reduce blood glucose in normoglycemic, non-diabetic mice; and, when co-administered with CS-917, enhances the suppression of hepatic glycogenolysis and achieves greater glucose-lowering effects than CS-917 alone in non-fasted Goto-Kakizaki (GK) rats.